Law360, New York (February 21, 2012, 4:53 PM ET) -- Precision BioSciences Inc. wasted no time firing off the latest salvo in its legal battle with rival Cellectis SA, filing two suits in North Carolina accusing France-based Cellectis of infringing genome engineering technology patents issued on Tuesday.
Each of Precision BioSciences' complaints asserted a patent just issued by the U.S. Patent and Trademark Office. Both patents relate to Prescision BioSciences' “directed nuclease editor” technology, which allows the production of genome-editing enzymes that insert, remove, modify and regulate genes in mammalian and plant cells, the plaintiff said....
Cellectis Hit With New Genome Engineering IP Suits
To view the full article, take a free trial now.
